London: A new study has added to mounting evidence that rosiglitazone - a drug used to treat type 2 diabetes - is associated with an increased risk of major heart problems.
Compared with pioglitazone, rosiglitazone was associated with a modest but statistically significant increased risk of heart attack (16%), congestive heart failure (23%), and mortality (14 %s). In certain groups of patients with type 2 diabetes, this may lead to 170 excess heart attacks, 649 excess cases of heart failure, and 431 excess deaths for every 100,000 patients who receive rosiglitazone rather than pioglitazone. Further adjusting the data to minimise bias, did not change the results significantly, suggesting that this is unlikely to be a chance finding, said the authors."Our findings have important implications," they wrote."Rosiglitazone is still available on a restricted basis in the United States and Canada. However, for patients who need thiazolidinedione treatment, continued use of rosiglitazone may lead to excess heart attacks, heart failure and mortality, compared with pioglitazone." The study has been published on bmj.com. ANI
Zee-Taleem Poll Survey on Elections 2014
Under gunpoint, I will choose Modi as PM: Kejriwal
Delhi gang-rape: Death upheld for 4 convicts
Is there a surge of support for Narendra Modi?